CA2222279C - Hypoxia inducible factor-1 and method of use - Google Patents

Hypoxia inducible factor-1 and method of use Download PDF

Info

Publication number
CA2222279C
CA2222279C CA2222279A CA2222279A CA2222279C CA 2222279 C CA2222279 C CA 2222279C CA 2222279 A CA2222279 A CA 2222279A CA 2222279 A CA2222279 A CA 2222279A CA 2222279 C CA2222279 C CA 2222279C
Authority
CA
Canada
Prior art keywords
hif
alpha
hypoxia
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2222279A
Other languages
English (en)
French (fr)
Other versions
CA2222279A1 (en
Inventor
Gregg L. Semenza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2222279A1 publication Critical patent/CA2222279A1/en
Application granted granted Critical
Publication of CA2222279C publication Critical patent/CA2222279C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Communication System (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2222279A 1995-06-06 1996-06-06 Hypoxia inducible factor-1 and method of use Expired - Lifetime CA2222279C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/480,473 1995-06-06
US08/480,473 US5882914A (en) 1995-06-06 1995-06-06 Nucleic acids encoding the hypoxia inducible factor-1
PCT/US1996/010251 WO1996039426A1 (en) 1995-06-06 1996-06-06 Hypoxia inducible factor-1 and method of use

Publications (2)

Publication Number Publication Date
CA2222279A1 CA2222279A1 (en) 1996-12-12
CA2222279C true CA2222279C (en) 2011-02-01

Family

ID=23908114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2222279A Expired - Lifetime CA2222279C (en) 1995-06-06 1996-06-06 Hypoxia inducible factor-1 and method of use

Country Status (9)

Country Link
US (3) US5882914A (enExample)
EP (2) EP1806357A1 (enExample)
JP (2) JPH11507541A (enExample)
AT (1) ATE355299T1 (enExample)
AU (1) AU704384B2 (enExample)
CA (1) CA2222279C (enExample)
DE (1) DE69636936T2 (enExample)
IL (1) IL118581A (enExample)
WO (1) WO1996039426A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU8536998A (en) * 1997-06-10 1998-12-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Regulatory sequences involved in hypoxia regulated gene expression and uses thereof
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US7074895B2 (en) 1997-08-21 2006-07-11 Quark Biotech, Inc. Sequences characteristic of hypoxia-regulated gene transcription
WO1999009046A1 (en) 1997-08-21 1999-02-25 Quark Biotech, Inc. Hypoxia-regulated genes
AU757930B2 (en) 1997-12-01 2003-03-13 Roche Diagnostics Gmbh Optimization of cells for endogenous gene activation
AU749467B2 (en) * 1997-12-04 2002-06-27 Genzyme Corporation Compositions and methods for inducing gene expression
WO1999048916A2 (en) * 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
US6124131A (en) 1998-08-25 2000-09-26 The Johns Hopkins University School Of Medicine Mutant hypoxia inducible factor-1 HIF-1
CA2341518A1 (en) * 1998-08-27 2000-03-09 Quark Biotech, Inc. Hypoxia regulated genes
US6436654B1 (en) * 1998-11-13 2002-08-20 Pharmacia & Upjohn Ab Methods for identifying compounds that modulate HIF-1α
SE9803891D0 (sv) * 1998-11-13 1998-11-13 Pharmacia & Upjohn Ab Protein Variants
JP4638098B2 (ja) * 1999-06-14 2011-02-23 キャンサー・リサーチ・テクノロジー・リミテッド 癌治療
WO2001023426A2 (en) * 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
FR2801319A1 (fr) * 1999-11-18 2001-05-25 Inst Nat Sante Rech Med Construction d'acide nucleique porteuse d'un systeme regulant l'expression d'un gene
US6893867B1 (en) 1999-12-23 2005-05-17 Keith A. Webster Molecular switch for regulating mammalian gene expression
CN1425075A (zh) * 2000-02-22 2003-06-18 牛津生物医学(英国)有限公司 差异表达筛选方法
AU2001290179B2 (en) * 2000-08-07 2007-07-12 Angiogenetics Sweden Ab Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
US7919274B2 (en) 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
WO2002094862A2 (en) * 2001-05-23 2002-11-28 Angiogene Inc. Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
DE60232443D1 (de) * 2001-06-05 2009-07-09 Masahiro Hiraoka Polypeptid-destabiliserendes protein in zellen unter aeroben bedingungen und dieses codierende dna
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
AU2003208684A1 (en) * 2002-03-05 2003-09-16 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
ES2649817T3 (es) * 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
CA2482904A1 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
NZ520321A (en) * 2002-07-19 2005-03-24 Auckland Uniservices Ltd Use of an agent adapted to inhibit HIF in use together with an antiangiogenic agent for treating tumours in a non- human animal
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
KR20120038546A (ko) * 2002-11-01 2012-04-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 HIF-1 알파의 siRNA 억제를 위한 조성물 및 방법
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20050014264A1 (en) * 2002-12-11 2005-01-20 University Of Massachusetts Method of introducing siRNA into adipocytes
WO2004066949A2 (en) 2003-01-28 2004-08-12 Rexahn Corporation Antisense oligonucleotides that inhibit expression of hif-1
ES2333794T3 (es) * 2003-01-31 2010-03-01 Rexahn Pharmaceuticals, Inc. Oligonucleotidos que inhiben la expresion de hif-1.
JP2007512369A (ja) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子1αアンタゴニストを用いる慢性関節リウマチの処置
WO2005056795A2 (en) * 2003-12-03 2005-06-23 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
NZ555644A (en) 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 hif―1 펩타이드와 vbc단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
CN100418574C (zh) * 2005-10-26 2008-09-17 王成球 一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
US20070122448A1 (en) * 2005-11-28 2007-05-31 Alireza Rezania Compositions and methods to create a vascularized environment for cellular transplantation
ES2596885T3 (es) 2006-06-07 2017-01-12 Genzyme Corporation Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la medula espinal
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. 血管新生のsiRNA阻害のための組成物及び方法
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
SI2497500T1 (sl) 2006-10-03 2017-01-31 Genzyme Corporation Genska terapija za spinalno mišično atrofijo
NZ598092A (en) * 2008-02-14 2012-07-27 Lincoln University Methods and compositions comprising specific strains of trichoderma atroviride for the biological control of soil borne plant pathogens and promoting plant growth
MX2011005851A (es) 2008-12-04 2011-07-29 Opko Opthalmics Llc Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
RS67077B1 (sr) 2009-05-02 2025-08-29 Genzyme Corp Genska terapija za neurodegenerativne poremećaje
EP4219708A3 (en) 2009-07-17 2023-10-11 Aaron Thomas Tabor Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
CA2895791A1 (en) * 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
JP6836400B2 (ja) 2014-03-28 2021-03-03 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション 乳がんおよび卵巣がんワクチン
GB201601527D0 (en) 2016-01-27 2016-03-09 Univ Southampton Hif-1 and Hif-2 inhibitors
US20230212296A1 (en) * 2020-06-02 2023-07-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for treating cancer
CN116024263A (zh) * 2022-09-23 2023-04-28 龙岩学院 一种高效表达猪HIF-1α基因的真核表达载体及其构建方法
WO2024211763A1 (en) * 2023-04-05 2024-10-10 The Johns Hopkins University Synthetic mrna encoding hif-1alpha and uses for wound healing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059131A1 (en) * 1989-06-23 1990-12-24 Ming-Shi Chang Compositions and methods for the synthesis of natriuretic protein receptor b and methods of use
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1

Also Published As

Publication number Publication date
EP0833840B1 (en) 2007-02-28
WO1996039426A1 (en) 1996-12-12
IL118581A0 (en) 1996-10-16
CA2222279A1 (en) 1996-12-12
AU704384B2 (en) 1999-04-22
JPH11507541A (ja) 1999-07-06
US5882914A (en) 1999-03-16
EP0833840A1 (en) 1998-04-08
EP0833840A4 (en) 2001-12-19
JP2009077729A (ja) 2009-04-16
AU6332696A (en) 1996-12-24
US6020462A (en) 2000-02-01
IL118581A (en) 2000-01-31
EP1806357A1 (en) 2007-07-11
ATE355299T1 (de) 2006-03-15
DE69636936D1 (de) 2007-04-12
DE69636936T2 (de) 2007-10-31
US6222018B1 (en) 2001-04-24

Similar Documents

Publication Publication Date Title
CA2222279C (en) Hypoxia inducible factor-1 and method of use
WO1996039426A9 (en) Hypoxia inducible factor-1 and method of use
Pevsner et al. n-Sec1: a neural-specific syntaxin-binding protein.
Yokoyama et al. SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene
Van den Berghe et al. FIF [fibroblast growth factor-2 (FGF-2)-interacting-factor], a nuclear putatively antiapoptotic factor, interacts specifically with FGF-2
Cheng et al. Calreticulin binds hYRNA and the 52-kDa polypeptide component of the Ro/SS-A ribonucleoprotein autoantigen
de la Brousse et al. Molecular and genetic characterization of GABP beta.
US5773583A (en) Methods and materials relating to the functional domains of DNA binding proteins
US5695963A (en) Endothelial PAS domain protein
AU6131194A (en) Tata-binding protein associated factors, nucleic acids encoding tafs, and methods of use
US20020119517A1 (en) Leptin induced genes
US5656595A (en) Peptides having GDP exchange factor activity, nucleic acid sequences coding for these peptides, preparation and use
US6297356B1 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
CA2281674A1 (en) Parg, a gtpase activating protein which interacts with ptpl1
CA2330228A1 (en) Angiostatin-binding protein
Lim et al. Characterization of the murine gene of gC1qBP, a novel cell protein that binds the globular heads of C1q, vitronectin, high molecular weight kininogen and factor XII
US6410713B1 (en) DNA encoding proteins that inhibit Hsp70 function
US6297019B1 (en) Recombinant polynucleotides encoding CYP7 promoter-binding factors
JPH10201491A (ja) タンパク質ホスファターゼ1結合タンパク質r5
JPH10117788A (ja) ヒト・myt−1キナーゼクローン
US6200776B1 (en) Polynucleotides encoding human sodium bicarbonate cotransporters
WO1993004076A1 (en) 141 transcription factor and methods of isolating same
KR20000049249A (ko) 전사 억제 및/또는 다른 단백질과의 상호작용에 관여하는지에이엑스 단백질 영역을 포함하는 폴리펩타이드, 상응하는핵산 및 이들의 용도
US6768003B1 (en) Nucleic acids that encode transcriptional adaptor proteins
JPH10506276A (ja) ヒト転写因子iia

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160606